PKO Investment Management Joint Stock Co Makes New Investment in Pfizer Inc. (NYSE:PFE)

PKO Investment Management Joint Stock Co purchased a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 79,000 shares of the biopharmaceutical company's stock, valued at approximately $2,096,000.

Several other institutional investors have also recently made changes to their positions in PFE. Northstar Financial Companies Inc. acquired a new position in shares of Pfizer during the 4th quarter worth approximately $854,000. Wealthedge Investment Advisors LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $207,000. Lighthouse Financial LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $301,000. Anchor Pointe Wealth Management LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $281,000. Finally, Mattson Financial Services LLC increased its holdings in shares of Pfizer by 95.7% during the 4th quarter. Mattson Financial Services LLC now owns 82,204 shares of the biopharmaceutical company's stock worth $2,379,000 after acquiring an additional 40,207 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Price Performance

Shares of PFE stock traded up $0.01 on Friday, hitting $23.46. 56,576,195 shares of the company's stock were exchanged, compared to its average volume of 41,238,850. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The stock has a market cap of $133.38 billion, a P/E ratio of 16.64, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The company has a 50 day moving average of $23.12 and a 200 day moving average of $25.07.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the prior year, the company earned $0.82 EPS. Pfizer's revenue for the quarter was down 7.8% on a year-over-year basis. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.33%. Pfizer's payout ratio is presently 124.64%.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of recent analyst reports. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group upped their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.